1. Studies of Hepatic Excretory Function
- Author
-
Kleiner Gj, Kresch L, and Arias Im
- Subjects
medicine.medical_specialty ,Population ,Toxicology ,Transport maximum ,Sulfobromophthalein ,Liver disease ,Contraceptive Agents ,Liver Function Tests ,Internal medicine ,Ethinylestradiol ,medicine ,Humans ,education ,Pharmacology ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Liver cell ,Sodium ,Mestranol ,Sodium, Dietary ,General Medicine ,medicine.disease ,Norethynodrel ,Metabolism ,Endocrinology ,Female ,business ,Liver function tests ,Contraceptives, Oral ,medicine.drug - Abstract
17-alpha-ethinyl-17-beta-hydroxy-5-(10) -estren-3-one (norethynodrel) and ethinylestradiol 3-methyl ether (mestranol) were administered intermittently and continuously in doses recommended for suppression of ovulation to women with neither clincial nor chemical evidence of liver disease. 24 women who were from 23-33 years of age were involved in the study. Reversible reduction of the hepatic transport maximum for bromsulfalein was observed; relative hepatic storage was unimpaired; and the dye was retained in plasma primarily as a conjugate. The administration of estradiol (2.5 mg per day for 10 days) did not alter the transport maximum the storage or the percentage of conjugated dye in plasma. The results suggest that the effect of norethynodrel and mestranol on bromsulfalein metabolism is probably related to the progestin that regularly interferes with the transfer of bromsulfalein conjugates from the liver cell into the bile. Light and electron microscopical and histochemical examinations of 2 liver biopsies were within normal limits. It is recommended that caution be exercised in the clinical use of these and related drugs in children or adults with hereditary developmental or acquired defects in hepatic excretory function.
- Published
- 1965